论文部分内容阅读
目的观察草酸铂联合希罗达治疗晚期大肠癌的疗效及安全性。方法73例晚期大肠癌患者随机分为两组,治疗组采用草酸铂85mg/m2静脉滴注2h,第1天,希罗达1 000mg/m2口服,第1～14d,每3周为一周期,对照组草酸铂85mg/m2静脉滴注3h,第1天,CF200mg/m2静脉滴注2h,第1～5d,5-Fu 300mg/m2静脉点滴5h,第1～5d,每3周为一个周期。每例患者至少接受4个疗程,按照WHO实体瘤近期客观疗效评定标准进行评价。结果治疗组(希罗达组)有效率50%,对照组有效率46.8%,无统计学意义(P>0.05),两组疗效相当。两组重度毒性反应,治疗组少于对照组,差异有统计学意义(P<0.05),其中重度白细胞减少,两组对比差异无统计学意义,而重度腹泻、便秘,重度口腔炎及重度恶心、呕吐,两组对比有统计学意义(P<0.05)。外周神经毒性为L-OHP的突出不良反应,呈可逆性。结论L-OHP联合希罗达治疗晚期结直肠癌疗效肯定,不良反应轻。有利于提高化疗患者的生存质量,患者乐于接受治疗,依从性好。
Objective To observe the efficacy and safety of oxaliplatin combined with Xeloda in the treatment of advanced colorectal cancer. Methods A total of 73 patients with advanced colorectal cancer were randomly divided into two groups. The treatment group received intravenous infusion of oxaliplatin 85mg / m2 for 2 hours. On the first day, the Xeloda 1000 mg / m2 orally, for the first to 14th days, , Control group oxaliplatin 85mg / m2 intravenous infusion of 3h, the first day, CF200mg / m2 intravenous infusion of 2h, 1 ~ 5d, 5-Fu 300mg / m2 intravenous drip 5h, 1 ~ 5d, every 3 weeks as a cycle. Each patient received at least 4 courses in accordance with the WHO objective assessment of objective curative effect of solid tumors. Results In the treatment group (Xeloda group), the effective rate was 50%, while that in the control group was 46.8%. There was no significant difference (P> 0.05). The curative effect was similar between the two groups. The two groups of severe toxicity, the treatment group less than the control group, the difference was statistically significant (P <0.05), including severe leukopenia, the two groups showed no significant difference between the contrast, and severe diarrhea, constipation, severe stomatitis and severe nausea , Vomiting, the two groups were statistically significant (P <0.05). Peripheral neurotoxicity is a prominent adverse reaction to L-OHP and is reversible. Conclusions L-OHP plus Xeloda is effective in treating advanced colorectal cancer with mild adverse reactions. Help to improve the quality of life of patients with chemotherapy, patients are willing to receive treatment, good compliance.